Raltegravir + FTC/TDF as HIV nPEP in MSMRaltegravir + FTC/TDF as HIV nPEP in MSM

This study investigates the safety, adherence and tolerability of RAL in a 3-drug combination for HIV nonoccupational post-exposure prophylaxis in men who have sex with men. HIV Medicine

Source: Medscape Today Headlines - December 30, 2013 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news